Xeris Biopharma Holdings Inc (NASDAQ:XERS) shares, rose in value, with the stock price down by -1.44% to the previous day’s close as strong demand from buyers drove the stock to $2.05.
Actively observing the price movement in the last trading, the stock closed the session at $2.08. The value of beta (5-year monthly) was 1.21. Referring to stock’s 52-week performance, its high was $3.26, and the low was $1.46. On the whole, XERS has fluctuated by -33.44% over the past month.
With the market capitalization of Xeris Biopharma Holdings Inc currently standing at about $287.92 million, investors are eagerly awaiting this quarter’s results, scheduled for Mar 06, 2024. As a result, investors might want to see an improvement in the stock’s price before the company announces its earnings report. Analysts are projecting the company’s earnings per share (EPS) to be -$0.12, which is expected to increase to -$0.09 for fiscal year -$0.38 and then to about -$0.22 by fiscal year 2025. Data indicates that the EPS growth is expected to be 15.60% in 2025, while the next year’s EPS growth is forecast to be 42.10%.
Analysts have estimated the company’s revenue for the quarter at $41.81 million, with a low estimate of $37.97 million and a high estimate of $44 million. According to the average forecast, sales growth in current quarter could jump up 25.90%, compared to the corresponding quarter of last year. Wall Street analysts also predicted that in 2025, the company’s y-o-y revenues would reach $184.43 million, representing an increase of 12.50% from the revenues reported in the last year’s results.
Revisions could be a useful indicator to get insight on short-term price movement; so for the company, there were no upward and no downward review(s) in last seven days. We see that XERS’s technical picture suggests that short-term indicators denote the stock is a 100% Sell on average. However, medium term indicators have put the stock in the category of 50% Buy while long term indicators on average have been pointing out that it is a 50% Sell.
The stock’s technical analysis shows that the PEG ratio is about 0, with the price of XERS currently trading nearly -6.16% and -20.34% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 35.82, while the 7-day volatility ratio is showing 5.11% which for the 30-day chart, stands at 6.79%. Furthermore, Xeris Biopharma Holdings Inc (XERS)’s beta value is 1.63, and its average true range (ATR) is 0.14.
A comparison of Xeris Biopharma Holdings Inc (XERS) with its peers suggests the former has fared considerably weaker in the market. XERS showed an intraday change of -1.44% in last session, and over the past year, it grew by 12.64%%.
Data on historical trading for Xeris Biopharma Holdings Inc (NASDAQ:XERS) indicates that the trading volumes over the past 10 days have averaged 1.46 million and over the past 3 months, they’ve averaged 2.35 million. According to company’s latest data on outstanding shares, there are 138.13 million shares outstanding.
Nearly 10.77% of Xeris Biopharma Holdings Inc’s shares belong to company insiders and institutional investors own 41.14% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 9.24 million shares as on Mar 15, 2024, resulting in a short ratio of 3.52. According to the data, the short interest in Xeris Biopharma Holdings Inc (XERS) stood at 6.58% of shares outstanding as of Mar 15, 2024; the number of short shares registered in Feb 15, 2024 reached 9.42 million. The stock has fallen by -12.77% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the XERS stock heading into the next quarter.
